Compare Innovative Industrial Properties Inc (IIPR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Innovative Industrial Properties Inc trades at $51.8 (market cap $1.43B), while Vertex Pharmaceuticals Incorporated trades at $511.21 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 89.2× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.64% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 86 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IIPR | VRTX | |
|---|---|---|
Market Cap | $1.43B | $127.55B |
Volume | 394,222 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $557.96 |
52-Week Low | $44.58 | $407.37 |
Typical Hold Time | 86 Days | 120 Days |
Enterprise Value | $1.96B | $121.68B |
Dividend Yield | 14.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.87, up 1.25% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings, beating in Q2 but missing in Q1, with revenue declining to $266 million in 2025. Valuation ratios appear attractive with a P/E of 11.75 and P/B of 0.83, while the company maintains a high net income margin of 52.27%. Recent news highlights a $245 million mezzanine loan commitment and a declared $1.90 dividend.
The outlook is cautious due to declining revenue and negative net cash flow in 2025, offset by strong profitability and a discounted valuation. Risks include tenant defaults and dividend sustainability concerns, but analyst consensus suggests upside with a $84.67 price target. The stock presents a high-yield opportunity with significant re-rating potential if operational challenges are managed.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
